Dementia Treatment Market Research Report - By Treatment Type (Antipsychotics, Cholinesterase Inhibitors, Memantine, Other (e.g., Monoamine oxidase B inhibitors, N-methyl-D-aspartate receptor antagonists)), By Stage of Dementia (Mild Dementia, Moderate Dementia, Severe Dementia), By Route of Administration (Oral, Transdermal, Injectable) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2032

Global Dementia Treatment Market Overview:

As per MRFR analysis, the Dementia Treatment Market Size was estimated at 11.7 (USD Billion) in 2022. The Dementia Treatment Market Industry is expected to grow from 12.13(USD Billion) in 2023 to 16.8 (USD Billion) by 2032. The Dementia Treatment Market CAGR (growth rate) is expected to be around 3.68% during the forecast period (2024 - 2032).

Key Dementia Treatment Market Trends Highlighted

The dementia treatment market is projected to witness significant growth in the coming years due to rising prevalence of the disease, advancements in diagnostic and therapeutic approaches, and the increasing geriatric population. One of the key drivers of this growth is the increasing incidence of dementia, specifically Alzheimer's disease, which is the most common type. The World Health Organization estimates that there are over 55 million people living with dementia worldwide, and this number is expected to triple by 2050.

There are several opportunities in the dementia treatment market that can be explored and captured. Research and development of novel drugs and therapies, including targeted therapies and disease-modifying treatments, is a major opportunity. Additionally, advancements in non-pharmacological interventions, such as cognitive stimulation therapy and lifestyle modifications, are gaining prominence. The increasing use of digital technologies for remote monitoring and disease management is another trend that is expected to shape the market in the coming years.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Dementia Treatment Market Drivers

Rising Prevalence of Dementia

One of the main drivers of the market is the growing incidence of dementia. Because the number of people living with this health condition will grow, many companies will have the potential to generate sufficient revenues. The main reasons for the growing incidence of dementia are longer life expectancy, the ability to diagnose the health condition under discussion, and the aging population.As a result, modern society has to address this issue, and many people look for effective treatments. Thus, it can be argued that the growing incidence of dementia is one of the major drivers of the Dementia Treatment Market Industry growth.

Growing Awareness and Acceptance of Dementia

Increased awareness and acceptance of dementia is another key market driver. In the past, dementia was often stigmatized and misunderstood. However, in recent years, there has been a growing movement to raise awareness about dementia and to reduce the stigma associated with it. This has led to a greater acceptance of dementia and an increased willingness to seek treatment. The growing awareness and acceptance of dementia are creating a more favorable environment for the development and adoption of new treatments.

Advancements in Research and Development

The increasing R activities are supporting the growth of the Dementia Treatment Market Industry. The researchers are constantly working on making more advanced and effective treatment options for dementia patients. These developments include different drugs, therapies, and devices. There are also several drugs that are in clinical trials that can slow down or stop the progression of the diseases. The highlighted development would help in expanding the size of the dementia treatment market.

Dementia Treatment Market Segment Insights:

Dementia Treatment Market Treatment Type Insights

In the Dementia Treatment Market, the Treatment Type segment is vital due to the high prevalence of dementia and the availability of numerous drug classes designed to manage various aspects of the condition. The four major classes of medications, such as Antipsychotics, Cholinesterase Inhibitors, Memantine, and Other Medications used to manage different symptoms of dementia, are in high demand and vital for the market. The types and variety of offerings allow the segment to capture the larger portion of the market share, with antipsychotics leading both in 2023 and further up to 2032 in the future.The class is used as therapy for a behavioral and psychological symptom of dementia and is highly efficient when it comes to controlling a patient’s agitation, aggression, and psychosis. Cholinesterase Inhibitors also play a critical role in their class and feature a different principle of operation. They function by stopping the activity of acetylcholine, a chemical substance that nerve cells in the brain use to communicate with one another, which facilitates an increase in acetylcholine levels. Memantine is another valuable drug that shows high efficiency being indicated for an application to treat moderate to severe Alzheimer’s type of dementia.The drug blocks the N-methyl-D-aspartate receptor on the neural cell. Finally, Monoamine oxidase B inhibitors, which are not present in the considered source, are another kind of medication from the Other Medications class, used to increase the dopamine level to restore a patient’s mood and motivation. N-methyl-D-aspartate receptor antagonists are also from the category and function by blocking the NMDA receptor to prevent excitotoxicity. Thus, the treatment type is likely to grow in the future period due to the high prevalence of the disease and the development of novel and more efficient treatments.At the same time, the potential market expansion is inhibited by the high costs of the therapies and the demand for individual approaches.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Dementia Treatment Market Stage of Dementia Insights

The Dementia Treatment Market is segmented by Stage of Dementia, which includes Mild Dementia, Moderate Dementia, and Severe Dementia. The Moderate Dementia segment is expected to grow at a CAGR of 3.68% from 2023 to 2032, and the Severe Dementia segment is expected to grow at a CAGR of 3.68% from 2023 to 2032. The growth of the Dementia Treatment Market is driven by the increasing prevalence of dementia, the rising geriatric population, and the growing demand for effective treatments.

Dementia Treatment Market Route of Administration Insights

The Dementia Treatment Market is segmented based on the Route of Administration into Oral, Transdermal, and Injectable. Among these, the Oral segment holds the largest market share due to the ease of administration, patient convenience, and cost-effectiveness. The Transdermal segment is projected to witness significant growth over the forecast period owing to the increasing adoption of non-invasive and sustained drug delivery methods. The Injectable segment, though smaller in size, caters to patients who cannot tolerate oral medications or require immediate drug delivery.Each route of administration offers unique advantages and disadvantages, influencing the treatment choices made by healthcare professionals. Understanding the dynamics of each segment is crucial for market participants to optimize their product portfolios and cater to the evolving needs of patients with dementia.

Dementia Treatment Market Regional Insights

The regional dispersion of the Dementia Treatment Market is divided into North America, Europe, APAC, South America, and MEA. North America is expected to dominate the market, with a market value of USD 3.79 billion in 2023 and an expected valuation of USD 4.5 billion by 2032, growing at a CAGR of 2.7%. Europe stands as the second-largest market, with a valuation of USD 2.9 billion in 2023 and projected to reach USD 3.6 billion by 2032, exhibiting a CAGR of 2.5%. The APAC region is anticipated to grow at a significant rate, with a market value of USD 2.3 billion in 2023 and a forecasted valuation of USD 3.2 billion by 2032, growing at a CAGR of 4.1%.South America is expected to contribute a market value of USD 1.2 billion in 2023 and is projected to reach USD 1.6 billion by 2032, growing at a CAGR of 3.4%. Lastly, MEA is expected to have a market value of USD 1.9 billion in 2023 and is projected to reach USD 2.5 billion by 2032, exhibiting a CAGR of 3.2%.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Dementia Treatment Market Key Players And Competitive Insights:

The dementia Treatment Market's competitive landscape is looking forward to hosting major companies that opt for mergers, joint ventures, and acquisitions in order to enhance their market presence across the globe. Key companies active in the Dementia Treatment Market involve their major focus on the R process, in turn, endowing the market with innovative revolutions in a broad range of dementia treatment segments. The accelerating prevalence of dementia across the worldwide population and surging demand for effective treatment options are too driving the remarkable developments in the market. Key companies in the market are integrated with numerous distribution chains and delivery methods, which is anticipated to uphold the Dementia Treatment Market competitive landscape in the forthcoming years.Eisai Co., Ltd.Eisai Co., Ltd. is a leading company actively operational in the dementia treatment market, with its major focus on R. The company is continuously in the development and assessment phases for various treatments, including small molecules and biologics, across its robust pipeline. Besides, Eisai Co., Ltd. is expanding its presence through mergers and acquisitions, wherein, in March 2022, it acquired Biogen's Alzheimer’s disease portfolio that includes Aduhelm is currently leading the blockbuster list of dementia treatment drugs.RocheRoche is among the major players operating in the Dementia Treatment Market and has its major focus on R activities. In its R pipeline, Roche has several developments, including gantenerumab, among others, which is in the final Phase 3 clinical trials. Further, the company is focusing on market expansion through mergers and acquisitions and in May 2021, it acquired Genentech, which provides itself with momentum for some of the launches under potential dementia treatment drugs.

Key Companies in the Dementia Treatment Market Include:

• Janssen Pharmaceutical


• HoffmannLa Roche Ltd.


• Endo Pharmaceuticals plc


• Merck Co.


• Astellas Pharma Inc


• Eisai Co. Ltd


• Shionogi Co. Ltd.


• Pfizer Inc


• Lundbeck A/S


• Biogen Idec


• Teva Pharmaceutical Industries Ltd


• Takeda Pharmaceutical Company Limited


• Allergan plc.


• Novartis AG


• Eli Lilly and Company

Dementia Treatment Market Industry Developments

The dementia treatment market is expected to witness substantial growth over the forecast period (2024-2032). The rising prevalence of dementia, increasing geriatric population, and growing awareness about the condition are key factors driving the market. The market is dominated by cholinesterase inhibitors and memantine, which are used to treat mild to moderate Alzheimer's disease. However, the emergence of novel therapies, such as monoclonal antibodies and tau-targeting drugs, is expected to reshape the market landscape in the coming years.Recent news developments include the approval of aducanumab by the FDA in June 2021, the first new Alzheimer's drug approved in nearly two decades. Other promising therapies, such as lecanemab and gantenerumab, are currently in late-stage clinical trials and could potentially revolutionize the treatment of dementia. Furthermore, several companies are investing in research on non-pharmacological interventions, such as cognitive training and lifestyle modifications, which could play a significant role in managing dementia symptoms.

Dementia Treatment Market Segmentation Insights

Dementia Treatment Market Treatment Type Outlook

• Antipsychotics


• Cholinesterase Inhibitors


• Memantine


• Other (e.g., Monoamine oxidase B inhibitors, N-methyl-D-aspartate receptor antagonists)

Dementia Treatment Market Stage of Dementia Outlook

• Mild Dementia


• Moderate Dementia


• Severe Dementia

Dementia Treatment Market Route of Administration Outlook

• Oral


• Transdermal


• Injectable

Dementia Treatment Market Regional Outlook

• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa